Bulimia Nervosa

Psychiatric MONDO:0005452 Pathograph 10 Eating Disorder Mental Health Disorder

Bulimia nervosa is an eating disorder characterized by recurrent binge eating episodes followed by compensatory behaviors intended to prevent weight gain, commonly including self-induced vomiting, fasting, laxative misuse, or excessive exercise.

Ask OpenScientist

Ask a research question about Bulimia Nervosa. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
6
Phenotypes
10
Pathograph
1
Genes
4
Treatments
2
Differentials
11
References
1
Deep Research
⚙

Pathophysiology

5
Polygenic and Environmental Liability
Bulimia nervosa is modeled as a complex eating disorder arising from interacting genetic, environmental, and psychological factors rather than a single Mendelian cause.
Downstream
Serotonergic Dysregulation Multifactorial eating-disorder liability is represented upstream of treatment-relevant neurotransmitter dysregulation.
Show evidence (1 reference)
DOI:10.65031/rzeq8592 SUPPORT Human Clinical
"Eating disorders (EDs) are complex, multifactorial conditions influenced by biological, psychological and environmental factors."
Review evidence supports multifactorial liability for eating disorders, including bulimia nervosa.
Serotonergic Dysregulation
Serotonin-linked biology is represented as a treatment-relevant disease mechanism because serotonergic pharmacotherapy reduces core binge-eating and vomiting outcomes in randomized bulimia nervosa trials.
response to serotonin link ⚠ ABNORMAL
Downstream
Loss-of-Control Binge Eating Serotonin-linked mechanisms are modeled upstream of binge-eating vulnerability.
Compensatory Purging Behavior Serotonin-linked mechanisms are also represented upstream of compensatory purging outcomes measured in treatment trials.
Show evidence (1 reference)
DOI:10.1192/bjp.166.5.660 SUPPORT Human Clinical
"Compared with placebo, fluoxetine treatment resulted in significantly greater reductions in vomiting (F [1,360] = 14.73, P< 0.0001) and binge-eating (F [1,360] = 14.39, P=0.0002) episodes per week at endpoint and improvement in other outcome measures."
Randomized clinical trial evidence supports fluoxetine effects on the core binge-purge episode outcomes.
Loss-of-Control Binge Eating
Bulimia nervosa includes recurrent episodes of excessive food intake, represented as the proximal eating-behavior event in the binge-purge cycle.
Downstream
Compensatory Purging Behavior Binge-eating episodes are followed by compensatory behaviors intended to prevent weight gain.
Binge Eating Episodes The pathophysiologic binge-eating event maps to the clinical abnormal eating phenotype.
Show evidence (1 reference)
DOI:10.3389/fpsyg.2024.1386347 SUPPORT Human Clinical
"BN is characterized by individuals’ episodes of excessive eating of food followed by engaging in unusual compensatory behaviors to control weight gain in BN."
Review evidence supports excessive eating episodes as part of the defining binge-purge cycle.
Compensatory Purging Behavior
Compensatory behaviors such as self-induced vomiting are represented as a distinct event downstream of binge eating and upstream of physical complications.
Downstream
Vomiting Self-induced vomiting is a purging behavior and a measurable clinical phenotype.
Purging-Related Physiologic Perturbation Recurrent purging can produce electrolyte and oral/salivary complications.
Show evidence (1 reference)
DOI:10.3389/fpsyg.2024.1386347 SUPPORT Human Clinical
"BN is characterized by individuals’ episodes of excessive eating of food followed by engaging in unusual compensatory behaviors to control weight gain in BN."
Review evidence supports compensatory behaviors as the event following excessive eating episodes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bulimia Nervosa Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Digestive 1
Vomiting Vomiting (HP:0002013)
Show evidence (1 reference)
DOI:10.1186/s40360-023-00713-7 SUPPORT Human Clinical
"Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint."
The systematic review identifies vomiting episodes as a primary bulimia nervosa outcome.
Head and Neck 1
Dental Erosion Abnormal dental enamel morphology (HP:0000682)
Show evidence (1 reference)
PMID:28972588 SUPPORT Human Clinical
"While there is consensus that bulimic behaviour directly causes dental erosion due to vomiting and acidic food choices, there is less clear evidence for a direct link between bulimia nervosa and dental caries, although there does still appear to be an association."
Oral-health review evidence directly supports dental erosion as a vomiting-related bulimia nervosa complication.
Metabolism 1
Hypokalemia Hypokalemia (HP:0002900)
Show evidence (1 reference)
PMID:11746288 SUPPORT Human Clinical
"The substantial frequency of hypokalemia and hypochloremia underscores the importance of an appropriate medical assessment for individuals with this disorder."
Controlled clinical evidence supports hypokalemia as a bulimia nervosa complication requiring medical assessment.
Nervous System 2
Binge Eating Episodes Abnormal eating behavior (HP:0100738)
Show evidence (1 reference)
DOI:10.1186/s40360-023-00713-7 SUPPORT Human Clinical
"Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint."
The systematic review identifies binge-eating episodes as a primary bulimia nervosa outcome.
Depressive Symptoms Depression (HP:0000716)
Show evidence (1 reference)
DOI:10.1002/erv.2582 SUPPORT Human Clinical
"This study examined the effect of family‐based treatment for bulimia nervosa (FBT‐BN) and cognitive behavioral therapy for adolescents (CBT‐A) on depressive symptoms and self‐esteem in adolescents with BN."
The trial context directly identifies depressive symptoms as a clinical comorbidity target in adolescents with bulimia nervosa.
Other 1
Parotid Gland Enlargement Enlargement of parotid gland (HP:0011801)
Show evidence (1 reference)
PMID:29618874 SUPPORT Human Clinical
"A 32-year-old woman had severe bilateral parotid sialomegaly for the last 6 years, which had occurred secondary to bulimia nervosa, which she had since 14 years."
Case-report and literature-review evidence supports parotid enlargement as a bulimia-associated salivary-gland complication.
🧬

Genetic Associations

1
Complex eating-disorder genetic liability (Risk Factor)
Show evidence (1 reference)
DOI:10.1101/2024.10.20.24315825 SUPPORT Human Clinical
"Eating disorders arise from a complex interaction of genetic and environmental influences."
Population-register study supports complex genetic and environmental liability for eating disorders, including bulimia nervosa.
💊

Treatments

4
Cognitive Behavioral Therapy
Action: cognitive behavior therapy MAXO:0000883
CBT is a psychosocial intervention used in bulimia nervosa treatment and is part of the evidence base for eating-disorder care.
Show evidence (1 reference)
DOI:10.3389/fpsyg.2024.1386347 SUPPORT Human Clinical
"Treatment practices included both pharmacological and psychosocial interventions, such as cognitive behavioral therapy (CBT) and limited motivational interviewing (MI)."
Review evidence supports CBT as a psychosocial treatment used for bulimia nervosa.
Family-Based Therapy for Adolescents
Action: Family Therapy NCIT:C93347
Family-based treatment for bulimia nervosa is used in adolescents and can improve bulimia nervosa symptoms alongside depressive symptoms and self-esteem.
Show evidence (1 reference)
DOI:10.1002/erv.2582 SUPPORT Human Clinical
"This study examined the effect of family‐based treatment for bulimia nervosa (FBT‐BN) and cognitive behavioral therapy for adolescents (CBT‐A) on depressive symptoms and self‐esteem in adolescents with BN."
Randomized adolescent BN trial evidence supports FBT-BN as a treatment modality for adolescent bulimia nervosa.
Fluoxetine Pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Agent: fluoxetine ↗
Fluoxetine is an SSRI pharmacotherapy with randomized trial evidence for reducing vomiting and binge-eating episode frequency in bulimia nervosa.
Show evidence (1 reference)
DOI:10.1192/bjp.166.5.660 SUPPORT Human Clinical
"Fluoxetine appeared to be safe and effective in patients with bulimia nervosa for up to 16 weeks."
Randomized clinical trial evidence supports fluoxetine pharmacotherapy for bulimia nervosa.
SSRI and Antidepressant Pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Agent: Selective Serotonin Reuptake Inhibitor ↗
Pharmacotherapies including SSRIs, TCAs, MAOIs, topiramate, lithium, and fenfluramine have been evaluated for bulimia nervosa, with mixed but symptom-reducing effects across trials.
Show evidence (1 reference)
DOI:10.1186/s40360-023-00713-7 SUPPORT Human Clinical
"This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant."
Systematic review evidence supports pharmacotherapy as symptom-reducing while noting limited overall efficacy.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Bulimia Nervosa:

Anorexia Nervosa MONDO:0005351
Overlapping Features Anorexia nervosa binge-eating/purging presentations can overlap with bulimia nervosa through binge eating and compensatory behaviors.
Distinguishing Features
  • Anorexia nervosa requires significantly low body weight or persistent restriction leading to low weight; bulimia nervosa does not require low body weight and is defined by recurrent binge eating with compensatory behaviors.
Show evidence (1 reference)
PMID:25591200 SUPPORT Human Clinical
"For low-weight patients with anorexia nervosa, virtually all physiologic systems are affected, ranging from hypotension and osteopenia to life-threatening arrhythmias, often requiring emergent assessment and hospitalization for metabolic stabilization."
Clinical review evidence supports anorexia nervosa as a low-weight differential diagnosis when binge/purge symptoms overlap with bulimia nervosa.
Binge Eating Disorder MONDO:0005582
Overlapping Features Binge eating disorder overlaps with bulimia nervosa through recurrent binge eating and loss of control.
Distinguishing Features
  • Binge eating disorder lacks regular compensatory behaviors such as self-induced vomiting, laxative misuse, fasting, or excessive exercise.
Show evidence (1 reference)
DOI:10.3389/fpsyg.2024.1386347 SUPPORT Human Clinical
"BN is characterized by individuals’ episodes of excessive eating of food followed by engaging in unusual compensatory behaviors to control weight gain in BN."
Bulimia nervosa's compensatory behaviors distinguish it from binge eating disorder when recurrent binge eating overlaps.
{ }

Source YAML

click to show 
name: Bulimia Nervosa
creation_date: "2026-04-28T00:00:00Z"
updated_date: "2026-04-28T15:27:23Z"
category: Psychiatric
description: >-
  Bulimia nervosa is an eating disorder characterized by recurrent binge eating
  episodes followed by compensatory behaviors intended to prevent weight gain,
  commonly including self-induced vomiting, fasting, laxative misuse, or
  excessive exercise.
disease_term:
  preferred_term: bulimia nervosa
  term:
    id: MONDO:0005452
    label: bulimia nervosa
parents:
- Eating Disorder
- Mental Health Disorder
pathophysiology:
- name: Polygenic and Environmental Liability
  description: >-
    Bulimia nervosa is modeled as a complex eating disorder arising from
    interacting genetic, environmental, and psychological factors rather than a
    single Mendelian cause.
  downstream:
  - target: Serotonergic Dysregulation
    description: >-
      Multifactorial eating-disorder liability is represented upstream of
      treatment-relevant neurotransmitter dysregulation.
  evidence:
  - reference: DOI:10.65031/rzeq8592
    reference_title: "Epigenetics of eating disorders: from genetic and molecular pathways to therapeutic possibilities"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eating disorders (EDs) are complex, multifactorial conditions influenced
      by biological, psychological and environmental factors.
    explanation: >-
      Review evidence supports multifactorial liability for eating disorders,
      including bulimia nervosa.
- name: Serotonergic Dysregulation
  description: >-
    Serotonin-linked biology is represented as a treatment-relevant disease
    mechanism because serotonergic pharmacotherapy reduces core binge-eating
    and vomiting outcomes in randomized bulimia nervosa trials.
  biological_processes:
  - preferred_term: response to serotonin
    term:
      id: GO:1904014
      label: response to serotonin
    modifier: ABNORMAL
  downstream:
  - target: Loss-of-Control Binge Eating
    description: >-
      Serotonin-linked mechanisms are modeled upstream of binge-eating
      vulnerability.
  - target: Compensatory Purging Behavior
    description: >-
      Serotonin-linked mechanisms are also represented upstream of
      compensatory purging outcomes measured in treatment trials.
  evidence:
  - reference: DOI:10.1192/bjp.166.5.660
    reference_title: Long-Term Fluoxetine Treatment of Bulimia Nervosa
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with placebo, fluoxetine treatment resulted in significantly
      greater reductions in vomiting (F [1,360] = 14.73, P< 0.0001) and
      binge-eating (F [1,360] = 14.39, P=0.0002) episodes per week at endpoint
      and improvement in other outcome measures.
    explanation: >-
      Randomized clinical trial evidence supports fluoxetine effects on the
      core binge-purge episode outcomes.
- name: Loss-of-Control Binge Eating
  description: >-
    Bulimia nervosa includes recurrent episodes of excessive food intake,
    represented as the proximal eating-behavior event in the binge-purge cycle.
  downstream:
  - target: Compensatory Purging Behavior
    description: >-
      Binge-eating episodes are followed by compensatory behaviors intended to
      prevent weight gain.
  - target: Binge Eating Episodes
    description: >-
      The pathophysiologic binge-eating event maps to the clinical abnormal
      eating phenotype.
  evidence:
  - reference: DOI:10.3389/fpsyg.2024.1386347
    reference_title: "Bulimia nervosa and treatment-related disparities: a review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BN is characterized by individuals’ episodes of excessive eating of food
      followed by engaging in unusual compensatory behaviors to control weight
      gain in BN.
    explanation: >-
      Review evidence supports excessive eating episodes as part of the
      defining binge-purge cycle.
- name: Compensatory Purging Behavior
  description: >-
    Compensatory behaviors such as self-induced vomiting are represented as a
    distinct event downstream of binge eating and upstream of physical
    complications.
  downstream:
  - target: Vomiting
    description: >-
      Self-induced vomiting is a purging behavior and a measurable clinical
      phenotype.
  - target: Purging-Related Physiologic Perturbation
    description: >-
      Recurrent purging can produce electrolyte and oral/salivary complications.
  evidence:
  - reference: DOI:10.3389/fpsyg.2024.1386347
    reference_title: "Bulimia nervosa and treatment-related disparities: a review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BN is characterized by individuals’ episodes of excessive eating of food
      followed by engaging in unusual compensatory behaviors to control weight
      gain in BN.
    explanation: >-
      Review evidence supports compensatory behaviors as the event following
      excessive eating episodes.
- name: Purging-Related Physiologic Perturbation
  description: >-
    Recurrent purging is represented upstream of electrolyte, dental, and
    salivary-gland complications commonly monitored in bulimia nervosa.
  downstream:
  - target: Hypokalemia
    description: Electrolyte depletion can manifest clinically as hypokalemia.
  - target: Dental Erosion
    description: Recurrent vomiting can damage dental surfaces.
  - target: Parotid Gland Enlargement
    description: Recurrent purging can be associated with salivary-gland enlargement.
  evidence:
  - reference: PMID:11746288
    reference_title: "Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal eating patterns and recurrent purging behaviors can result in
      significant medical complications.
    explanation: >-
      Clinical laboratory evidence supports modeling purging as upstream of
      physiologic medical complications.
phenotypes:
- name: Binge Eating Episodes
  description: >-
    Recurrent binge-eating episodes are a core clinical manifestation of
    bulimia nervosa. HPO does not currently provide a specific binge-eating
    term in the local ontology cache, so this uses the closest broader term.
  phenotype_term:
    preferred_term: Binge eating episodes
    term:
      id: HP:0100738
      label: Abnormal eating behavior
  evidence:
  - reference: DOI:10.1186/s40360-023-00713-7
    reference_title: "Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary outcomes were changes in the frequency of binge eating episodes
      and vomiting episodes from baseline to endpoint.
    explanation: >-
      The systematic review identifies binge-eating episodes as a primary
      bulimia nervosa outcome.
- name: Vomiting
  description: >-
    Self-induced vomiting may be used as a compensatory behavior after binge
    eating.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: DOI:10.1186/s40360-023-00713-7
    reference_title: "Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary outcomes were changes in the frequency of binge eating episodes
      and vomiting episodes from baseline to endpoint.
    explanation: >-
      The systematic review identifies vomiting episodes as a primary bulimia
      nervosa outcome.
- name: Hypokalemia
  description: >-
    Hypokalemia is a clinically important electrolyte abnormality monitored as
    a purging-related complication.
  phenotype_term:
    preferred_term: Hypokalemia
    term:
      id: HP:0002900
      label: Hypokalemia
  evidence:
  - reference: PMID:11746288
    reference_title: "Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The substantial frequency of hypokalemia and hypochloremia underscores
      the importance of an appropriate medical assessment for individuals with
      this disorder.
    explanation: >-
      Controlled clinical evidence supports hypokalemia as a bulimia nervosa
      complication requiring medical assessment.
- name: Dental Erosion
  description: >-
    Dental erosion can occur as an oral complication of recurrent vomiting in
    purging presentations.
  phenotype_term:
    preferred_term: Dental erosion
    term:
      id: HP:0000682
      label: Abnormal dental enamel morphology
  evidence:
  - reference: PMID:28972588
    reference_title: "The impact of bulimia nervosa on oral health: A review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While there is consensus that bulimic behaviour directly causes dental
      erosion due to vomiting and acidic food choices, there is less clear
      evidence for a direct link between bulimia nervosa and dental caries,
      although there does still appear to be an association.
    explanation: >-
      Oral-health review evidence directly supports dental erosion as a
      vomiting-related bulimia nervosa complication.
- name: Parotid Gland Enlargement
  description: >-
    Parotid gland enlargement can occur as a salivary-gland complication in
    purging presentations.
  phenotype_term:
    preferred_term: Enlargement of parotid gland
    term:
      id: HP:0011801
      label: Enlargement of parotid gland
  evidence:
  - reference: PMID:29618874
    reference_title: "Bilateral Parotid Sialadenosis Associated with Long-Standing Bulimia: A Case Report and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 32-year-old woman had severe bilateral parotid sialomegaly for the last
      6 years, which had occurred secondary to bulimia nervosa, which she had
      since 14 years.
    explanation: >-
      Case-report and literature-review evidence supports parotid enlargement
      as a bulimia-associated salivary-gland complication.
- name: Depressive Symptoms
  description: >-
    Depressive symptoms are a clinically important psychiatric manifestation
    and comorbidity context in adolescents with bulimia nervosa.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: DOI:10.1002/erv.2582
    reference_title: "Comorbid depressive symptoms and self‐esteem improve after either cognitive‐behavioural therapy or family‐based treatment for adolescent bulimia nervosa"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study examined the effect of family‐based treatment for bulimia
      nervosa (FBT‐BN) and cognitive behavioral therapy for adolescents
      (CBT‐A) on depressive symptoms and self‐esteem in adolescents with BN.
    explanation: >-
      The trial context directly identifies depressive symptoms as a clinical
      comorbidity target in adolescents with bulimia nervosa.
genetic:
- name: Complex eating-disorder genetic liability
  association: Risk Factor
  notes: >-
    Bulimia nervosa is represented as complex and polygenic; current entry
    does not assert a single causal gene.
  evidence:
  - reference: DOI:10.1101/2024.10.20.24315825
    reference_title: "Shared Genetic Architecture Between Eating Disorders, Mental Health Conditions, and Cardiometabolic Diseases: A Comprehensive Population-Wide Study Across Two Countries"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eating disorders arise from a complex interaction of genetic and
      environmental influences.
    explanation: >-
      Population-register study supports complex genetic and environmental
      liability for eating disorders, including bulimia nervosa.
treatments:
- name: Cognitive Behavioral Therapy
  description: >-
    CBT is a psychosocial intervention used in bulimia nervosa treatment and is
    part of the evidence base for eating-disorder care.
  treatment_term:
    preferred_term: cognitive behavior therapy
    term:
      id: MAXO:0000883
      label: cognitive behavior therapy
  evidence:
  - reference: DOI:10.3389/fpsyg.2024.1386347
    reference_title: "Bulimia nervosa and treatment-related disparities: a review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment practices included both pharmacological and psychosocial
      interventions, such as cognitive behavioral therapy (CBT) and limited
      motivational interviewing (MI).
    explanation: >-
      Review evidence supports CBT as a psychosocial treatment used for bulimia
      nervosa.
- name: Family-Based Therapy for Adolescents
  description: >-
    Family-based treatment for bulimia nervosa is used in adolescents and can
    improve bulimia nervosa symptoms alongside depressive symptoms and
    self-esteem.
  treatment_term:
    preferred_term: Family Therapy
    term:
      id: NCIT:C93347
      label: Family Therapy
  evidence:
  - reference: DOI:10.1002/erv.2582
    reference_title: Comorbid depressive symptoms and self-esteem improve after either cognitive-behavioural therapy or family-based treatment for adolescent bulimia nervosa
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study examined the effect of family‐based treatment for bulimia
      nervosa (FBT‐BN) and cognitive behavioral therapy for adolescents (CBT‐A)
      on depressive symptoms and self‐esteem in adolescents with BN.
    explanation: >-
      Randomized adolescent BN trial evidence supports FBT-BN as a treatment
      modality for adolescent bulimia nervosa.
- name: Fluoxetine Pharmacotherapy
  description: >-
    Fluoxetine is an SSRI pharmacotherapy with randomized trial evidence for
    reducing vomiting and binge-eating episode frequency in bulimia nervosa.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fluoxetine
      term:
        id: CHEBI:5118
        label: fluoxetine
  evidence:
  - reference: DOI:10.1192/bjp.166.5.660
    reference_title: Long-Term Fluoxetine Treatment of Bulimia Nervosa
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fluoxetine appeared to be safe and effective in patients with bulimia
      nervosa for up to 16 weeks.
    explanation: >-
      Randomized clinical trial evidence supports fluoxetine pharmacotherapy for
      bulimia nervosa.
- name: SSRI and Antidepressant Pharmacotherapy
  description: >-
    Pharmacotherapies including SSRIs, TCAs, MAOIs, topiramate, lithium, and
    fenfluramine have been evaluated for bulimia nervosa, with mixed but
    symptom-reducing effects across trials.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Selective Serotonin Reuptake Inhibitor
      term:
        id: NCIT:C94725
        label: Selective Serotonin Reuptake Inhibitor
  evidence:
  - reference: DOI:10.1186/s40360-023-00713-7
    reference_title: "Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This meta-analysis indicates that most pharmacotherapies decreased the
      frequency of binge-eating and vomiting episodes, body weight, and
      depressive symptoms in BN patients, but the efficacy was not significant.
    explanation: >-
      Systematic review evidence supports pharmacotherapy as symptom-reducing
      while noting limited overall efficacy.
differential_diagnoses:
- name: Anorexia Nervosa
  description: >-
    Anorexia nervosa binge-eating/purging presentations can overlap with
    bulimia nervosa through binge eating and compensatory behaviors.
  distinguishing_features:
  - >-
    Anorexia nervosa requires significantly low body weight or persistent
    restriction leading to low weight; bulimia nervosa does not require low
    body weight and is defined by recurrent binge eating with compensatory
    behaviors.
  disease_term:
    preferred_term: anorexia nervosa
    term:
      id: MONDO:0005351
      label: anorexia nervosa
  evidence:
  - reference: PMID:25591200
    reference_title: Initial evaluation, diagnosis, and treatment of anorexia nervosa and bulimia nervosa.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For low-weight patients with anorexia nervosa, virtually all physiologic
      systems are affected, ranging from hypotension and osteopenia to
      life-threatening arrhythmias, often requiring emergent assessment and
      hospitalization for metabolic stabilization.
    explanation: >-
      Clinical review evidence supports anorexia nervosa as a low-weight
      differential diagnosis when binge/purge symptoms overlap with bulimia
      nervosa.
- name: Binge Eating Disorder
  description: >-
    Binge eating disorder overlaps with bulimia nervosa through recurrent binge
    eating and loss of control.
  distinguishing_features:
  - >-
    Binge eating disorder lacks regular compensatory behaviors such as
    self-induced vomiting, laxative misuse, fasting, or excessive exercise.
  disease_term:
    preferred_term: binge eating disorder
    term:
      id: MONDO:0005582
      label: binge eating disorder
  evidence:
  - reference: DOI:10.3389/fpsyg.2024.1386347
    reference_title: "Bulimia nervosa and treatment-related disparities: a review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BN is characterized by individuals’ episodes of excessive eating of food
      followed by engaging in unusual compensatory behaviors to control weight
      gain in BN.
    explanation: >-
      Bulimia nervosa's compensatory behaviors distinguish it from binge eating
      disorder when recurrent binge eating overlaps.
references:
- reference: DOI:10.3389/fpsyg.2024.1386347
  title: "Bulimia nervosa and treatment-related disparities: a review"
  findings: []
- reference: DOI:10.1186/s40360-023-00713-7
  title: "Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis"
  findings: []
- reference: DOI:10.1192/bjp.166.5.660
  title: Long-Term Fluoxetine Treatment of Bulimia Nervosa
  findings: []
- reference: DOI:10.5694/mja2.52008
  title: Current approaches in the recognition and management of eating disorders
  findings: []
- reference: DOI:10.65031/rzeq8592
  title: "Epigenetics of eating disorders: from genetic and molecular pathways to therapeutic possibilities"
  findings: []
- reference: DOI:10.1101/2024.10.20.24315825
  title: "Shared Genetic Architecture Between Eating Disorders, Mental Health Conditions, and Cardiometabolic Diseases: A Comprehensive Population-Wide Study Across Two Countries"
  findings: []
- reference: DOI:10.1002/erv.2582
  title: Comorbid depressive symptoms and self-esteem improve after either cognitive-behavioural therapy or family-based treatment for adolescent bulimia nervosa
  findings: []
- reference: PMID:11746288
  title: "Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study."
  findings: []
- reference: PMID:28972588
  title: "The impact of bulimia nervosa on oral health: A review of the literature."
  findings: []
- reference: PMID:29618874
  title: "Bilateral Parotid Sialadenosis Associated with Long-Standing Bulimia: A Case Report and Literature Review."
  findings: []
- reference: PMID:25591200
  title: Initial evaluation, diagnosis, and treatment of anorexia nervosa and bulimia nervosa.
  findings: []
📚

References & Deep Research

References

11
DOI:10.3389/fpsyg.2024.1386347
Bulimia nervosa and treatment-related disparities: a review
No top-level findings curated for this source.
DOI:10.1186/s40360-023-00713-7
Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
No top-level findings curated for this source.
DOI:10.1192/bjp.166.5.660
Long-Term Fluoxetine Treatment of Bulimia Nervosa
No top-level findings curated for this source.
DOI:10.5694/mja2.52008
Current approaches in the recognition and management of eating disorders
No top-level findings curated for this source.
DOI:10.65031/rzeq8592
Epigenetics of eating disorders: from genetic and molecular pathways to therapeutic possibilities
No top-level findings curated for this source.
DOI:10.1101/2024.10.20.24315825
Shared Genetic Architecture Between Eating Disorders, Mental Health Conditions, and Cardiometabolic Diseases: A Comprehensive Population-Wide Study Across Two Countries
No top-level findings curated for this source.
DOI:10.1002/erv.2582
Comorbid depressive symptoms and self-esteem improve after either cognitive-behavioural therapy or family-based treatment for adolescent bulimia nervosa
No top-level findings curated for this source.
PMID:11746288
Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study.
No top-level findings curated for this source.
PMID:28972588
The impact of bulimia nervosa on oral health: A review of the literature.
No top-level findings curated for this source.
PMID:29618874
Bilateral Parotid Sialadenosis Associated with Long-Standing Bulimia: A Case Report and Literature Review.
No top-level findings curated for this source.
PMID:25591200
Initial evaluation, diagnosis, and treatment of anorexia nervosa and bulimia nervosa.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 44 citations 2026-04-28T10:13:45.410530

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Bulimia Nervosa
  • MONDO ID: (if available)
  • Category: Psychiatric

Research Objectives

Please provide a comprehensive research report on Bulimia Nervosa covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Bulimia Nervosa (BN) — Disease Characteristics Research Report (Psychiatric)

Executive summary

Bulimia nervosa (BN) is a feeding/eating disorder characterized by recurrent episodes of binge eating with loss of control followed by compensatory behaviors (e.g., self-induced vomiting, laxatives, fasting, excessive exercise), with self-evaluation unduly influenced by shape/weight concerns. DSM-5 requires symptoms on average at least weekly for 3 months; DSM-5 also grades severity by compensatory behavior frequency. BN is common, often undertreated, and associated with substantial morbidity including electrolyte abnormalities and cardiovascular complications, as well as elevated suicide risk. Recent (2023–2025) burden analyses using Global Burden of Disease (GBD) data show rising prevalence/incidence/DALYs globally, with pronounced SDI and regional heterogeneity. Evidence-based care is anchored in psychological therapies (CBT-E/CBT-BN; family-based therapy in adolescents) with adjunct pharmacotherapy (notably fluoxetine 60 mg/day) and emerging digital/neuromodulation approaches.

1. Disease information

1.1 Concise overview

BN is defined by recurrent binge-eating episodes with a sense of loss of control and compensatory behaviors to prevent weight gain, occurring at least weekly for at least 3 months, with undue influence of shape/weight on self-evaluation, and not occurring exclusively during anorexia nervosa. (wilson2024bulimianervosaand pages 2-3)

1.2 Key identifiers

  • ICD-11: 6B81 Bulimia nervosa (explicitly listed in a 2023 rapid review) (hay2023epidemiologyofeating pages 1-2)
  • ICD-10: commonly mapped clinically as F50.2 (note: not directly sourced in retrieved primary texts; included here only as a commonly used mapping and should be verified in an ICD crosswalk) (hay2023epidemiologyofeating pages 1-2)
  • MeSH / MONDO / OMIM / Orphanet: Not retrieved in the available full-text sources within this tool run; should be added from ontology databases (gap).

1.3 Synonyms / alternative names

  • “Bulimia”
  • “Binge–purge disorder” (used descriptively in clinical contexts; not a distinct ICD-11 entity in the retrieved sources)

1.4 Evidence sources (patient-level vs aggregated)

This report synthesizes (i) aggregated epidemiology and burden estimates from GBD analyses (population-level modeling) and (ii) clinical trial and systematic review evidence from peer-reviewed literature (study-level aggregated clinical outcomes). (ge2025globalregionaland pages 2-4, goldstein1995longtermfluoxetinetreatment pages 1-2)

2. Etiology

2.1 Disease causal factors (current understanding)

BN is best understood as multifactorial with contributions from genetic liability, environmental exposures, and psychological traits. A 2023 pharmacotherapy meta-analysis background summarizes that eating disorders are “multifactorial, with genetic predisposition, environmental factors, and psychological characteristics involved.” (yu2023efficacyofpharmacotherapies pages 1-2)

2.2 Risk factors

Psychological/behavioral and social-developmental risk factors (adolescents): A 2025 pediatric narrative review describes BN in youth as linked to emotional dysregulation, impulsivity, deficits in self-regulation, and psychosocial triggers including puberty-related challenges, peer pressure, and societal beauty ideals. (horovitz2025advancementsinthe pages 1-2)

Mood disturbance and comorbidity (risk/maintenance): Binge eating may be “triggered by dysphoric mood” and accompanied by depression and self-criticism. A large review summarized comorbidity patterns with mood disorders (43%) and anxiety disorders (53%), and that ~80–90% of BN patients may have had at least one lifetime mood disorder episode (mostly depressive). (yu2023efficacyofpharmacotherapies pages 1-2)

2.3 Protective factors

Not clearly specified in the retrieved sources (gap). Prevention/intervention-focused public health strategies are suggested by GBD burden authors, but explicit protective factors are not enumerated. (liu2025globaltrendsand pages 2-3, ge2025globalregionaland pages 2-4)

2.4 Gene–environment interactions and epigenetic mediation

A 2024 review emphasizes that epigenetic mechanisms may mediate environmental and genetic risks across eating disorders, highlighting DNA methylation and stating that “epigenetic mechanisms serve as key mediators of environmental and genetic risk factors” and that dynamic methylation changes may influence disordered eating through altered gene expression. (wong2024epigeneticsofeating pages 1-2)

3. Phenotypes

3.1 Core behavioral and cognitive/affective phenotypes

  • Recurrent binge eating with loss of control (DSM-aligned). (wilson2024bulimianervosaand pages 2-3)
  • Compensatory behaviors: self-induced vomiting; misuse of laxatives/diuretics/enemas; fasting; excessive exercise. (wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3)
  • Self-evaluation strongly influenced by shape/weight. (wilson2024bulimianervosaand pages 2-3)
  • Youth-associated affective features: intense shame/guilt after binges, emotional dysregulation, impulsivity. (horovitz2025advancementsinthe pages 1-2)

3.2 Phenotype characteristics

  • Typical onset: adolescence/early adulthood; one review reports median age of onset ~12.4 years. (wilson2024bulimianervosaand pages 1-2)
  • Course: relapsing course is common; one review cites ~80% remission “with proper treatment,” but details vary by study and setting. (wilson2024bulimianervosaand pages 2-3)

3.3 Quality-of-life impact

Delayed identification reduces quality of life and increases comorbidity risk in primary care contexts; highlighted as a key rationale for screening/early intervention. (kozmer2025accuracyandsuitability pages 1-6)

3.4 Suggested HPO terms (examples; should be validated against HPO)

Behavioral: - Binge eating → HP:0033256 (Binge eating) (suggested) - Self-induced vomiting → HP:0002013 (Vomiting) (suggested) - Laxative misuse (no single HPO term; may map to medication misuse / purging behavior) Cognitive/affective: - Body image disturbance (map to terms capturing distorted body image; specific HPO term should be confirmed) - Impulsivity → HP:0000710 (Impulsivity) (suggested)

(horovitz2025advancementsinthe pages 1-2, wilson2024bulimianervosaand pages 2-3)

4. Genetic/molecular information

4.1 Genetic architecture (current evidence)

Heritability evidence supports a meaningful genetic component for BN. - A 2024 epigenetics review reports twin-study heritability for BN ~55%–62%. (wong2024epigeneticsofeating pages 1-2) - A population-register study across Denmark/Sweden reports moderate heritability for BN diagnosis (~39%), and notes substantial heritability for core behaviors including binge eating and self-induced vomiting. (meijsen2025sharedgeneticarchitecture pages 1-4) - Symptom-level heritability estimates reported include self-induced vomiting ~72% in females and a range for binge eating across sexes/samples; the authors emphasize that symptom genetics and clinical course remain under-studied. (davies2025mappingthegenetic pages 5-8)

4.2 Causal genes / pathogenic variants

No single-gene causal variants for BN were identified in the retrieved sources; BN is discussed as polygenic/multifactorial. (meijsen2025sharedgeneticarchitecture pages 1-4, wong2024epigeneticsofeating pages 1-2)

4.3 Epigenetics

DNA methylation is highlighted as a likely mediator of environmental/genetic risk in eating disorders broadly, with current limitations including sample size and biomarker scarcity. (wong2024epigeneticsofeating pages 1-2)

4.4 Gene–environment interactions

A 2025 symptom-onset genetics preprint emphasizes interplay: “genetic risk interacts with early environment and sex-at-birth” (general statement; not BN-specific mechanistic GxE). (davies2025mappingthegenetic pages 5-8)

Suggested GO biological process terms (examples): - Regulation of feeding behavior (confirm GO ID) - Reward processing / dopaminergic signaling (confirm GO IDs) - DNA methylation (e.g., GO:0006306; confirm)

5. Environmental information

5.1 Environmental and lifestyle contributors

Recent reviews emphasize socio-cultural and personal experiential contributors (e.g., beauty ideals, peer pressure), with adolescence as a vulnerable developmental window. (horovitz2025advancementsinthe pages 1-2, wong2024epigeneticsofeating pages 1-2)

5.2 Infectious agents

Not applicable based on retrieved evidence (no pathogen-triggered etiology described).

6. Mechanism / pathophysiology

6.1 Conceptual causal chain (current consensus framing)

A practical mechanistic framing supported by the retrieved clinical literature is: 1) underlying vulnerability (genetic liability + environmental/psychological stressors) (yu2023efficacyofpharmacotherapies pages 1-2, meijsen2025sharedgeneticarchitecture pages 1-4) 2) episodes of loss-of-control eating (binge eating), often mood-triggered (yu2023efficacyofpharmacotherapies pages 1-2) 3) compensatory behaviors (purging/non-purging) leading to physiologic perturbations (dehydration, electrolyte abnormalities) (alharbi2024effectivetreatmentapproaches pages 5-6) 4) downstream medical complications (cardiovascular, dental/oral, GI, respiratory) and psychiatric morbidity/suicidality (wilson2024bulimianervosaand pages 1-2)

6.2 Epigenetic mediation hypothesis

Epigenetics is proposed as a bridge between environmental exposures and gene expression changes relevant to disordered eating behaviors, particularly via DNA methylation. (wong2024epigeneticsofeating pages 1-2)

6.3 Molecular profiling / biomarkers

The epigenetics review notes that biomarker research “significantly lags behind” for eating disorders; no validated BN biomarker diagnostic was identified in retrieved sources. (wong2024epigeneticsofeating pages 1-2)

Suggested CL cell types (examples; confirm in Cell Ontology): - Neuron (CL:0000540) - GABAergic neuron (as implicated in ED transcriptomics in related work; not BN-specific in retrieved evidence) (ahmed2025psychologicalapproachesfor pages 3-6)

7. Anatomical structures affected

BN affects multiple organ systems primarily through binge/purge behaviors.

7.1 Organ-level (examples)

  • Cardiovascular system: electrolyte disturbances increase cardiovascular risk including ischemic heart disease; “abnormal heartbeat patterns” are cited in inpatient-indication criteria. (wilson2024bulimianervosaand pages 1-2, alharbi2024effectivetreatmentapproaches pages 5-6)
  • Oral cavity and salivary glands: dental erosion; salivary gland hypertrophy. (wilson2024bulimianervosaand pages 1-2)
  • Pharynx/esophagus: pharyngeal trauma; esophageal damage from vomiting. (wilson2024bulimianervosaand pages 1-2, horovitz2025advancementsinthe pages 1-2)
  • Respiratory system: aspiration pneumonia risk. (wilson2024bulimianervosaand pages 1-2)
  • Gastrointestinal tract: bloating, dysphagia, acid reflux. (wilson2024bulimianervosaand pages 2-3)
  • Reproductive/endocrine: irregular menses. (wilson2024bulimianervosaand pages 2-3)

7.2 Suggested UBERON terms (examples; confirm)

  • Heart (UBERON:0000948)
  • Esophagus (UBERON:0001043)
  • Salivary gland (UBERON:0001836)
  • Tooth (UBERON:0001091)
  • Stomach (UBERON:0000945)

8. Temporal development

8.1 Onset

Evidence indicates typical onset in adolescence/early adulthood, with median onset reported as ~12.4 years in one 2024 review; another synthesis reports average onset 16–17 years. (wilson2024bulimianervosaand pages 1-2, yu2023efficacyofpharmacotherapies pages 1-2)

8.2 Progression/course

BN can be chronic with relapse; prognosis is variable and influenced by psychological factors and treatment timing. (wilson2024bulimianervosaand pages 2-3)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

Sex-specific pooled prevalence (global): A 2023 MJA review table reports BN prevalence estimates: - 12-month: women 0.7%, men 0.4% - Lifetime: women 1.9%, men 0.6% - Point: women 1.5%, men 0.1% (hay2023currentapproachesin pages 2-3, hay2023currentapproachesin media 4293f313)

GBD 2021 global burden (BN-specific): A 2025 GBD analysis reports global increases from 1990 to 2021: - Incident cases: 5,595,035 → 8,227,657 - Prevalent cases: 7,416,420 → 12,367,024 - DALYs: 1,564,211 → 2,604,702 with increasing ASRs (EAPCs: prevalence 0.66; incidence 0.55; DALYs 0.67). (ge2025globalregionaland pages 2-4)

SDI disparities (2021): High-SDI ASPR 311.26/100,000 vs Low-SDI 96.69/100,000; high-SDI DALYs rate 65.38/100,000 vs low-SDI 20.31/100,000. (ge2025globalregionaland pages 2-4)

Country example (Iran, GBD 2019): BN ASPR 186.42/100,000 (2019). (amiri2025trendsprevalenceincidence pages 1-2)

9.2 Inheritance pattern

BN is consistent with complex/polygenic inheritance with moderate-to-high heritability estimates. (meijsen2025sharedgeneticarchitecture pages 1-4, wong2024epigeneticsofeating pages 1-2)

10. Diagnostics

10.1 Clinical criteria

DSM-5-aligned clinical features summarized in a 2024 review include: binge eating with loss of control, recurrent compensatory behaviors, frequency at least weekly for 3 months, undue influence of weight/shape on self-evaluation, and exclusion of anorexia nervosa. (wilson2024bulimianervosaand pages 2-3)

10.2 Diagnostic tests and instruments

  • EDE (Eating Disorder Examination) interview is described as the gold standard diagnostic interview; EDE-Q is its self-report derivative used for diagnostic assessment/psychopathology. (hay2023currentapproachesin pages 2-3)

10.3 Screening in real-world settings (primary care)

  • The MJA review states that screening measures “lack high levels of positive predictive power,” indicating false positives are common and positive screens should be followed by diagnostic evaluation. (hay2023currentapproachesin pages 2-3)
  • A 2025 BJGP Open primary-care screening systematic review reports for SCOFF (BN): sensitivity 97.88%–100% and specificity 89.6%–94.4%, noting increased false positives and reporting low PPV (~24.4% in one study). It also identifies implementation barriers: time constraints, stigma, and lack of trust in screening/clinicians. (kozmer2025accuracyandsuitability pages 14-18, kozmer2025accuracyandsuitability pages 1-6)

10.4 Biomarkers / imaging

No validated biomarker diagnostics for BN were identified in the retrieved sources; biomarker research is described as lagging. (wong2024epigeneticsofeating pages 1-2)

11. Outcome / prognosis

11.1 Morbidity and mortality

BN is associated with medical complications of purging (electrolyte abnormalities, cardiovascular disease) and elevated mortality and suicide risk. A 2024 review reports standardized mortality in BN of ~1.5–2.5% and suicide risk ~8-fold versus the general population. (wilson2024bulimianervosaand pages 1-2)

11.2 Treatment seeking and disparities (real-world implementation)

A 2024 review reports that ~85–94% of people with BN “never seek or delay treatment,” often delaying by 4–5 years. Reviewed RCT samples were predominantly female and White, suggesting evidence gaps for males and racial minorities and potential disparities in access and representation. (wilson2024bulimianervosaand pages 1-2)

12. Treatment

12.1 Evidence-based psychological therapies

  • CBT-E is described as first-line for adults and typically delivered over ~20 weekly sessions for BN. (hay2023currentapproachesin pages 2-3)
  • In adolescents, evidence supports FBT-BN and CBT variants. A 109-participant RCT reported end-of-treatment abstinence 39.4% (FBT-BN) vs 19.7% (CBT-A) and 6-month abstinence 44% vs 25.4%, favoring FBT-BN. (alharbi2024effectivetreatmentapproaches pages 5-6)

12.2 Pharmacotherapy

Fluoxetine 60 mg/day: A multicenter double-blind placebo-controlled trial (1995) in DSM-III-R BN patients randomized 398 (3:1 fluoxetine 60 mg/day vs placebo) found significantly greater reductions in vomiting and binge-eating episodes, concluding fluoxetine was safe and effective up to 16 weeks. (goldstein1995longtermfluoxetinetreatment pages 1-2)

Medication class evidence (meta-analysis): A 2023 systematic review/meta-analysis of 33 studies across multiple drug classes reported pooled improvements vs placebo in binge eating (SMD -0.40), vomiting (SMD -0.16), depressive symptoms (SMD -0.32), and weight (WMD -3.05 kg), with increased dropout due to adverse events (RR 1.66). (yu2023efficacyofpharmacotherapies pages 1-2)

12.3 Emerging interventions

Emerging/adjunct approaches include virtual reality-assisted therapy, neuromodulation (e.g., rTMS), and digitally delivered CBT (including guided internet-based CBT trial protocols), with evidence still developing. (lynch2025eatingdisordersclinical pages 3-4, wilson2024bulimianervosaand pages 2-3)

12.4 MAXO term suggestions

See Treatment Evidence Table (artifact-02).

13. Prevention

High-quality BN-specific primary prevention trials were not identified in the retrieved sources; however, burden analyses emphasize prevention and early intervention as priorities given projected increases. (liu2025globaltrendsand pages 2-3, ge2025globalregionaland pages 2-4)

Practical prevention-related actions supported by the diagnostic literature include: - Secondary prevention: screening (with appropriate follow-up due to false positives) and early referral pathways in primary care. (kozmer2025accuracyandsuitability pages 14-18, hay2023currentapproachesin pages 2-3)

14. Other species / natural disease

No naturally occurring BN analogue in other species was identified in the retrieved sources (gap).

15. Model organisms

No BN-specific validated animal model details were retrieved in this tool run (gap).

Recent developments (2023–2025 highlights)

1) Global burden quantification and projections: BN-specific GBD analyses (1990–2021; projections to 2030) quantify rising incident and prevalent cases and DALYs, with SDI and regional heterogeneity. (ge2025globalregionaland pages 2-4) 2) Primary-care screening evidence synthesis: Updated synthesis of screening tool accuracy/suitability in primary care highlights high sensitivity but imperfect specificity and implementation barriers. (kozmer2025accuracyandsuitability pages 14-18, kozmer2025accuracyandsuitability pages 1-6) 3) Expanding mechanistic framing via epigenetics: Reviews highlight DNA methylation and epigenetic mediation as a plausible pathway linking environment and genetic risk, while noting biomarker gaps. (wong2024epigeneticsofeating pages 1-2)

Embedded summary artifacts

Disease Category Key identifiers DSM-5 core diagnostic features DSM-5 severity specifier Key diagnostic/screening instruments
Bulimia nervosa (BN) Psychiatric; feeding/eating disorder ICD-11: 6B81; ICD-10 commonly mapped as F50.2; DSM-5 feeding and eating disorder (hay2023epidemiologyofeating pages 1-2) Recurrent binge-eating episodes with loss of control plus recurrent inappropriate compensatory behaviors (for example self-induced vomiting, laxative/diuretic misuse, fasting, or excessive exercise), occurring on average at least once weekly for 3 months; self-evaluation unduly influenced by body shape/weight; disturbance does not occur exclusively during anorexia nervosa (wilson2024bulimianervosaand pages 2-3, yu2023efficacyofpharmacotherapies pages 1-2) Severity based on average number of inappropriate compensatory behaviors per week: Mild 1–3; Moderate 4–7; Severe 8–13; Extreme 14+ (wilson2024bulimianervosaand pages 1-2) EDE (Eating Disorder Examination) diagnostic interview = gold standard; EDE-Q self-report derivative used for diagnostic assessment/psychopathology; brief screening tools: SCOFF and SDE (Screen for Disordered Eating), with SCOFF widely used and SDE noted as highly sensitive; SCOFF sensitivity for BN in primary care reported at 97.88%–100% with specificity 89.6%–94.4% (hay2023currentapproachesin pages 2-3, kozmer2025accuracyandsuitability pages 1-6)

Table: This table summarizes the core identifiers, DSM-5 diagnostic features, severity specifier, and commonly used diagnostic/screening tools for bulimia nervosa. It is useful as a compact reference for disease ontology mapping and clinical diagnosis.

Source Year Journal URL / DOI Population / scope Key bulimia nervosa estimates Citation
Hay et al. 2023 Medical Journal of Australia https://doi.org/10.5694/mja2.52008 Global pooled prevalence estimates 12-month prevalence: women 0.7%, men 0.4%; Lifetime prevalence: women 1.9%, men 0.6%; Point prevalence: women 1.5%, men 0.1% (hay2023currentapproachesin pages 2-3, hay2023currentapproachesin media 4293f313)
Ge et al. 2025 Journal of Eating Disorders https://doi.org/10.1186/s40337-025-01289-9 Global GBD 1990–2021 Incident cases rose from 5,595,035 (1990) to 8,227,657 (2021); prevalent cases from 7,416,420 to 12,367,024; DALYs from 1,564,211 to 2,604,702; global EAPCs: prevalence 0.66 (95% UI 0.61–0.71), incidence 0.55 (0.52–0.58), DALYs 0.67 (0.62–0.72) (ge2025globalregionaland pages 2-4)
Ge et al. 2025 Journal of Eating Disorders https://doi.org/10.1186/s40337-025-01289-9 2021 SDI-stratified burden High SDI: ASPR 311.26/100,000 (95% UI 211.22–435.75), ASIR 159.5/100,000 (101.9–230.34), age-standardized DALYs 65.38/100,000 (37.29–106.61); Low SDI: ASPR 96.69/100,000 (62.85–140.31), ASIR 82.94/100,000 (51.73–124.85), age-standardized DALYs 20.31/100,000 (11.42–33.98) (ge2025globalregionaland pages 2-4)
Amiri & Hosseini 2025 Eating and Weight Disorders https://doi.org/10.1007/s40519-025-01769-6 Iran, GBD 2019 BN age-standardized prevalence rate (ASPR) 186.42 per 100,000 in 2019; overall ED ASPR 254/100,000 (UI 189–328); overall ED DALYs 53.94/100,000 (UI 33.53–80.20) (amiri2025trendsprevalenceincidence pages 1-2)
Liu et al. 2025 The British Journal of Psychiatry https://doi.org/10.1192/bjp.2025.10450 Ages 15–29 years, global GBD 1990–2021 BN incidence increased 44.68% from 298.24 to 351.29 per 100,000; ASR increase 17.79%; incidence EAPC 0.56 (95% UI 0.53–0.58); BN total cases increased 53.18%; BN DALYs increased 53.12% with ASR increase 22.39% and DALY EAPC 0.72 (liu2025globaltrendsand pages 2-3)

Table: This table compiles key recent bulimia nervosa epidemiology and burden estimates from pooled prevalence reviews and GBD-based analyses. It is useful for quickly comparing sex-specific prevalence, global burden trends, SDI disparities, and country-specific rates.

Treatment Population / setting Evidence / study details Key outcomes Suggested MAXO term Citation
CBT-E / CBT-BN (first-line psychotherapy) Adults with BN; typically outpatient CBT-E is described as first-line for adults and is typically delivered over 20 weekly sessions for bulimia nervosa; unified meta-analysis of CBT across adult mental disorders found effect sizes for BN between 0.5 and 1.0 vs inactive controls First-line adult psychotherapy; moderate efficacy range in meta-analysis; used in routine care and guidelines MAXO: cognitive behavioral psychotherapy (hay2023currentapproachesin pages 2-3)
FBT-BN vs CBT-A Adolescents aged 12–18 with DSM-5 BN or partial BN RCT summarized in 2024 review: 109 adolescents randomized to FBT-BN or CBT-A, 18 sessions over 6 months Abstinence at end of treatment 39.4% vs 19.7% (p=0.04) favoring FBT-BN; at 6 months 44.0% vs 25.4% (p=0.03); no significant difference at 12 months MAXO: family therapy (alharbi2024effectivetreatmentapproaches pages 5-6)
Family-based therapy (FBT) vs CBT / supportive psychotherapy Adolescents with BN Three high-quality RCTs summarized in review Remission higher with FBT vs CBT: 39% vs 20%; higher with FBT vs supportive psychotherapy: 39% vs 18%; similar to guided self-help CBT in one trial (10% vs 14%) MAXO: family therapy (alharbi2024effectivetreatmentapproaches pages 5-6)
Fluoxetine 60 mg/day Adult outpatients with BN Double-blind multicenter trial at 15 US clinics; 483 entered, 398 randomized (3:1 fluoxetine 60 mg/day vs placebo), 225 completed over 16 weeks Greater reductions in vomiting (F[1,360]=14.73, P<0.0001) and binge-eating (F[1,360]=14.39, P=0.0002) vs placebo; judged safe on adverse event, vital sign, and lab analyses MAXO: selective serotonin reuptake inhibitor therapy (goldstein1995longtermfluoxetinetreatment pages 1-2)
Pharmacotherapy overall (all drug classes pooled) BN patients across RCTs 2023 systematic review/meta-analysis of 33 studies, 11 drugs, 6 drug classes: TCAs, SSRIs, MAOIs, antiepileptics, lithium, fenfluramine vs placebo: binge-eating frequency SMD -0.40 (95% CI -0.61 to -0.19); vomiting SMD -0.16 (-0.30 to -0.03); depressive symptoms SMD -0.32 (-0.51 to -0.13); weight WMD -3.05 kg (-5.97 to -0.13); dropout due to adverse events RR 1.66 (1.14 to 2.41) MAXO: pharmacotherapy (yu2023efficacyofpharmacotherapies pages 1-2)
SSRIs (class; includes fluoxetine, citalopram, fluvoxamine) BN patients in RCTs Most studied drug class in 2023 meta-analysis (14 SSRI trials) Contribute to pooled reductions in binge eating and vomiting; fluoxetine is the best-established SSRI and specifically supported at 60 mg/day MAXO: selective serotonin reuptake inhibitor therapy (yu2023efficacyofpharmacotherapies pages 1-2, goldstein1995longtermfluoxetinetreatment pages 1-2)
TCAs / MAOIs / topiramate and other agents BN patients in RCTs Included in pooled 2023 meta-analysis: 8 TCA trials, 6 MAOI trials, 3 topiramate trials, plus lithium and fenfluramine Drug effects varied by class; pooled benefits were statistically favorable but authors concluded overall efficacy remained limited/heterogeneous MAXO: antidepressant therapy / antiepileptic therapy (yu2023efficacyofpharmacotherapies pages 1-2)
Guided internet-based CBT (ICBT) + treatment as usual Women with BN; multicenter Japan trial protocol 2023 multicenter assessor-blinded RCT protocol comparing ICBT + TAU vs TAU at 7 institutions; outcomes include binge eating + purging, ED severity, depression, anxiety, QoL, satisfaction Emerging digital implementation strategy aimed at improving access; efficacy results pending in protocol paper MAXO: telehealth cognitive behavioral psychotherapy (yu2023efficacyofpharmacotherapies pages 1-2)
Other emerging interventions (DBT, ICAT, VR, PED-t, rTMS, D-cycloserine, motivational interviewing) Mostly outpatient adult BN studies 2024 treatment-disparities review of 17 RCTs reported trials of multiple psychosocial and adjunctive approaches beyond CBT Evidence base is smaller than for CBT/FBT; reviewed as adjunctive or alternative modalities rather than established first-line care MAXO: dialectical behavior therapy / virtual reality therapy / transcranial magnetic stimulation (wilson2024bulimianervosaand pages 2-3, lynch2025eatingdisordersclinical pages 3-4)

Table: This table summarizes key bulimia nervosa treatments across psychotherapy, pharmacotherapy, and emerging digital or neuromodulatory approaches. It highlights study design, trial size, quantitative outcomes, and suggested MAXO mappings to support knowledge-base annotation.

Visual evidence

Bulimia nervosa sex-stratified prevalence estimates (12-month, lifetime, and point prevalence) are shown in the extracted Box 2 table from the 2023 MJA review. (hay2023currentapproachesin media 4293f313)

Limitations of this report (evidence gaps)

  • MONDO/MeSH/OMIM/Orphanet identifiers were not retrieved from ontology databases in this tool run; these should be added from authoritative ontology sources.
  • BN-specific GWAS loci/genes and variant-level annotations were not available in retrieved sources; evidence here is largely heritability and conceptual mechanistic framing.
  • Model organisms and cross-species evidence were not retrieved.
  • Biomarker diagnostics are described as underdeveloped; no validated BN biomarker was identified.

Key source URLs (selected)

  • Hay et al., Med J Aust (2023-06): https://doi.org/10.5694/mja2.52008 (hay2023currentapproachesin pages 2-3)
  • Hay et al., J Eat Disord (2023-02): https://doi.org/10.1186/s40337-023-00738-7 (hay2023epidemiologyofeating pages 1-2)
  • Wilson & Kagabo, Front Psychol (2024-08): https://doi.org/10.3389/fpsyg.2024.1386347 (wilson2024bulimianervosaand pages 1-2)
  • Ge et al., J Eat Disord (2025-06): https://doi.org/10.1186/s40337-025-01289-9 (ge2025globalregionaland pages 2-4)
  • Yu et al., BMC Pharmacol Toxicol (2023-12): https://doi.org/10.1186/s40360-023-00713-7 (yu2023efficacyofpharmacotherapies pages 1-2)
  • Goldstein et al., Br J Psychiatry (1995-05): https://doi.org/10.1192/bjp.166.5.660 (goldstein1995longtermfluoxetinetreatment pages 1-2)
  • Kozmér et al., BJGP Open (2025-10): https://doi.org/10.3399/bjgpo.2025.0149 (kozmer2025accuracyandsuitability pages 1-6)

References

  1. (wilson2024bulimianervosaand pages 2-3): Kim Wilson and Robert Kagabo. Bulimia nervosa and treatment-related disparities: a review. Frontiers in Psychology, Aug 2024. URL: https://doi.org/10.3389/fpsyg.2024.1386347, doi:10.3389/fpsyg.2024.1386347. This article has 11 citations and is from a peer-reviewed journal.

  2. (hay2023epidemiologyofeating pages 1-2): Phillipa Hay, Phillip Aouad, Anvi Le, Peta Marks, Danielle Maloney, Sarah Barakat, Robert Boakes, Leah Brennan, Emma Bryant, Susan Byrne, Belinda Caldwell, Shannon Calvert, Bronny Carroll, David Castle, Ian Caterson, Belinda Chelius, Lyn Chiem, Simon Clarke, Janet Conti, Lexi Crouch, Genevieve Dammery, Natasha Dzajkovski, Jasmine Fardouly, John Feneley, Nasim Foroughi, Mathew Fuller-Tyszkiewicz, Anthea Fursland, Veronica Gonzalez-Arce, Bethanie Gouldthorp, Kelly Griffin, Scott Griffiths, Ashlea Hambleton, Amy Hannigan, Mel Hart, Susan Hart, Ian Hickie, Francis Kay-Lambkin, Ross King, Michael Kohn, Eyza Koreshe, Isabel Krug, Jake Linardon, Randall Long, Amanda Long, Sloane Madden, Siân McLean, Thy Meddick, Jane Miskovic-Wheatley, Deborah Mitchison, Richard O’Kearney, Roger Paterson, Susan Paxton, Melissa Pehlivan, Genevieve Pepin, Andrea Phillipou, Judith Piccone, Rebecca Pinkus, Bronwyn Raykos, Paul Rhodes, Elizabeth Rieger, Karen Rockett, Sarah Rodan, Janice Russell, Haley Russell, Fiona Salter, Susan Sawyer, Beth Shelton, Urvashnee Singh, Sophie Smith, Evelyn Smith, Karen Spielman, Sarah Squire, Juliette Thomson, Marika Tiggemann, Ranjani Utpala, Lenny Vartanian, Andrew Wallis, Warren Ward, Sarah Wells, Eleanor Wertheim, Simon Wilksch, Michelle Williams, Stephen Touyz, and Sarah Maguire. Epidemiology of eating disorders: population, prevalence, disease burden and quality of life informing public policy in australia—a rapid review. Journal of Eating Disorders, Feb 2023. URL: https://doi.org/10.1186/s40337-023-00738-7, doi:10.1186/s40337-023-00738-7. This article has 189 citations and is from a peer-reviewed journal.

  3. (ge2025globalregionaland pages 2-4): Yihao Ge, Shanshan Zhang, Zekun Li, Hongmin Guo, Xiaohan Li, Zhiyong Li, Fang Dong, and Feng Zhang. Global, regional and national level burden of bulimia nervosa from 1990 to 2021 and their projections to 2030: analysis of the global burden of disease study. Journal of Eating Disorders, Jun 2025. URL: https://doi.org/10.1186/s40337-025-01289-9, doi:10.1186/s40337-025-01289-9. This article has 1 citations and is from a peer-reviewed journal.

  4. (goldstein1995longtermfluoxetinetreatment pages 1-2): David J. Goldstein, Michael G. Wilson, Vicki L. Thompson, Janet H. Potvin, and Alvin H. Rampey. Long-term fluoxetine treatment of bulimia nervosa. British Journal of Psychiatry, 166:660-666, May 1995. URL: https://doi.org/10.1192/bjp.166.5.660, doi:10.1192/bjp.166.5.660. This article has 301 citations and is from a highest quality peer-reviewed journal.

  5. (yu2023efficacyofpharmacotherapies pages 1-2): Sijie Yu, Yuhan Zhang, Chongkai Shen, and Fei Shao. Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis. BMC Pharmacology and Toxicology, Dec 2023. URL: https://doi.org/10.1186/s40360-023-00713-7, doi:10.1186/s40360-023-00713-7. This article has 19 citations.

  6. (horovitz2025advancementsinthe pages 1-2): Omer Horovitz. Advancements in the diagnosis and treatment of eating disorders in children and adolescents: challenges, progress, and future directions. Nutrients, 17:1744, May 2025. URL: https://doi.org/10.3390/nu17101744, doi:10.3390/nu17101744. This article has 10 citations.

  7. (liu2025globaltrendsand pages 2-3): Lu Liu, Ke Wang, Mengqin Dai, Wenxiu Luo, Lei Tang, Xianghong Ding, Yun Liu, Liling Wu, Nian Liu, and Jiaming Luo. Global trends and future projections of eating disorders among adolescents and young adults: comprehensive analysis from 1990 to 2050 using eight machine-learning models. The British Journal of Psychiatry, pages 1-15, Nov 2025. URL: https://doi.org/10.1192/bjp.2025.10450, doi:10.1192/bjp.2025.10450. This article has 2 citations.

  8. (wong2024epigeneticsofeating pages 1-2): Chloe Wong, Sang Hyuck Lee, Ying-Young Hui, Gerome Breen, and Moritz Herle. Epigenetics of eating disorders: from genetic and molecular pathways to therapeutic possibilities. Cutting Edge Psychiatry in Practice, 6:18-25, Dec 2024. URL: https://doi.org/10.65031/rzeq8592, doi:10.65031/rzeq8592. This article has 0 citations.

  9. (wilson2024bulimianervosaand pages 1-2): Kim Wilson and Robert Kagabo. Bulimia nervosa and treatment-related disparities: a review. Frontiers in Psychology, Aug 2024. URL: https://doi.org/10.3389/fpsyg.2024.1386347, doi:10.3389/fpsyg.2024.1386347. This article has 11 citations and is from a peer-reviewed journal.

  10. (kozmer2025accuracyandsuitability pages 1-6): Stella Kozmér, Ruichen Yin, Joseph Evans, Alex Burns, and Jane Smith. Accuracy and suitability of eating disorder screening tools for binge eating disorder and bulimia nervosa in a primary care setting: a systematic review and narrative summary. BJGP Open, pages BJGPO.2025.0149, Oct 2025. URL: https://doi.org/10.3399/bjgpo.2025.0149, doi:10.3399/bjgpo.2025.0149. This article has 0 citations and is from a peer-reviewed journal.

  11. (meijsen2025sharedgeneticarchitecture pages 1-4): Joeri Meijsen, Kejia Hu, Dang Wei, Stefana Aicoboaie, Helena L Davies, Ruyue Zhang, Mischa Lundberg, Richard Zetterberg, Joëlle Pasman, Weimin Ye, Thomas Werge, Cynthia M. Bulik, Fang Fang, Alfonso Buil, and Nadia Micali. Shared genetic architecture between eating disorders, mental health conditions, and cardiometabolic diseases: a comprehensive population-wide study across two countries. MedRxiv, Oct 2025. URL: https://doi.org/10.1101/2024.10.20.24315825, doi:10.1101/2024.10.20.24315825. This article has 6 citations.

  12. (davies2025mappingthegenetic pages 5-8): Helena L. Davies, Abigail R. ter Kuile, Sang Hyuck Lee, Rujia Wang, Jessica Mundy, Zain-Ul-Abideen Ahmad, Jonathan Coleman, Saakshi Kakar, Emily Kelly, Chelsea Mika Malouf, Gursharan Kalsi, Moritz Herle, Gerome Breen, and Christopher Hübel. Mapping the genetic landscape of the age at onset and severity of eating disorder symptoms. MedRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.25.25336612, doi:10.1101/2025.09.25.25336612. This article has 0 citations.

  13. (alharbi2024effectivetreatmentapproaches pages 5-6): Yara Alharbi, Fatema Saleh, and Khaled A Shahat. Effective treatment approaches for eating disorders in children and adolescents: a review article. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.74003, doi:10.7759/cureus.74003. This article has 4 citations.

  14. (ahmed2025psychologicalapproachesfor pages 3-6): Fatema Ahmed, Chen Wu, Li Li, Qingyuan Ye, Waleed Ksebe, and Kefang Wang. Psychological approaches for eating disorders: the role of body image, self-esteem, and quality of life. Psychotherapy in the Third Millennium - Cross-Cutting Themes and Proposals for Reflection, Mar 2025. URL: https://doi.org/10.5772/intechopen.1009601, doi:10.5772/intechopen.1009601. This article has 4 citations.

  15. (hay2023currentapproachesin pages 2-3): Phillipa J. Hay, Rebekah M. Rankin, Lucie M. Ramjan, and J. Conti. Current approaches in the recognition and management of eating disorders. Medical Journal of Australia, 219:127-134, Jun 2023. URL: https://doi.org/10.5694/mja2.52008, doi:10.5694/mja2.52008. This article has 21 citations and is from a peer-reviewed journal.

  16. (hay2023currentapproachesin media 4293f313): Phillipa J. Hay, Rebekah M. Rankin, Lucie M. Ramjan, and J. Conti. Current approaches in the recognition and management of eating disorders. Medical Journal of Australia, 219:127-134, Jun 2023. URL: https://doi.org/10.5694/mja2.52008, doi:10.5694/mja2.52008. This article has 21 citations and is from a peer-reviewed journal.

  17. (amiri2025trendsprevalenceincidence pages 1-2): Sohrab Amiri and Seyed Morteza Hosseini. Trends, prevalence, incidence, and disability-adjusted life years of anorexia nervosa and bulimia nervosa in iran: global burden of disease study. Eating and Weight Disorders, Jul 2025. URL: https://doi.org/10.1007/s40519-025-01769-6, doi:10.1007/s40519-025-01769-6. This article has 0 citations.

  18. (kozmer2025accuracyandsuitability pages 14-18): Stella Kozmér, Ruichen Yin, Joseph Evans, Alex Burns, and Jane Smith. Accuracy and suitability of eating disorder screening tools for binge eating disorder and bulimia nervosa in a primary care setting: a systematic review and narrative summary. BJGP Open, pages BJGPO.2025.0149, Oct 2025. URL: https://doi.org/10.3399/bjgpo.2025.0149, doi:10.3399/bjgpo.2025.0149. This article has 0 citations and is from a peer-reviewed journal.

  19. (lynch2025eatingdisordersclinical pages 3-4): D. Lynch, H. Ogutlu, O. Gundogdu-Ogutlu, E. Barrett, and F. McNicholas. Eating disorders: clinical update. Irish Journal of Psychological Medicine, pages 1-5, Jan 2025. URL: https://doi.org/10.1017/ipm.2024.47, doi:10.1017/ipm.2024.47. This article has 2 citations.